BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Daval International Limited 

4a Gildredge Road
Eastbourne
East Sussex    BN21 4RL  United Kingdom
Phone: 0845-130-3014 Fax: 0845-603-1190


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Daval International Limited Release: Detailed Molecular Analysis of Aimspro® to be Presented at the 16th Conference in Genomics and Proteomics of Human Pathogens 27-28 June 6/27/2013 8:36:50 AM    More...
Daval International Limited Release: Open Label Clinical Study Results of AIMSPRO® in the Treatment of Progressive MS Suggest the Drug Stops Disease Progression and May Have Some Restorative Effects 6/3/2013 12:00:42 PM    More...
Daval International Limited Release: Results From an Open Label Clinical Study of AIMSPRO in the Treatment of Progressive Multiple Sclerosis to be Presented at the 2013 Annual Meeting of the Consortium of Multiple Sclerosis Centers, May 29-June 1 5/28/2013 10:02:17 AM    More...
Daval International Limited CSO Presents Results From an Exploratory Clinical Trial of AIMSPRO in Amyotrophic Lateral Sclerosis (ALS) at American Academy of Neurology Annual Meeting 3/21/2013 12:05:23 PM    More...
Daval International Limited Release: Results From an Exploratory Clinical Trial of AIMSPRO in Amyotrophic Lateral Sclerosis (ALS) to be Presented at AAN Annual Meeting 3/12/2013 10:11:06 AM    More...
Daval International Limited Announces Positive Phase II Results for AIMSPRO(R) as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma) 10/10/2011 7:01:22 AM    More...
Daval International Limited Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 7/20/2011 10:50:22 AM    More...
Daval International Limited Awarded Orphan Drug Designation for Motor Neurone Disease Treatment 11/9/2009 8:58:23 AM    More...
Daval International Limited: AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis 6/1/2009 8:37:54 AM    More...
Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R) 11/26/2007 8:25:30 AM    More...

//-->